The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12‐year experience in more than 900 patients
Abstract
Objectives This paper reviews a 12-year experience in more than 900 patients with spasmodic dysphonia who have been treated with botulinum toxin. Study design This is a retrospective analysis of patients with adductor spasmodic dysphonia (strain-strangled voice), abductor spasmodic dysphonia (whispering voice), and adductor breathing dystonia (paradoxical vocal fold motion), all of whom have been treated with botulinum toxin injections for relief of symptom. Methods All of the patients were studied with a complete head and neck and neurologic examination; fiberoptic laryngostroboscopy; acoustic and aerodynamic measures; and a speech evaluation including the Universal spasmodic dysphonia rating scale. Some were given electromyography. All patients received botulinum toxin injections into the affected muscles under electromyographic guidance. Results The adductor patients had an average benefit of 90% of normal function lasting an average of 15.1 weeks. The abductor patients had an average benefit of 66.7% of normal function lasting an average of 10.5 weeks. Adverse effects included mild breathiness and coughing on fluids in the adductor patients, and mild stridor in a few of the abductor patients. Conclusion Botulinum toxin A injection of the laryngeal hyperfunctional muscles has been found over the past 12 years to be the treatment of choice to control the dystonic symptoms in most patients with spasmodic dysphonia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Traditionally, perceptual measures of voice quality have been reported as a measure of speech activity in SD”
From The consequences of spasmodic dysphonia on communication-related quality of life: A qualitative study of the insider's experiences (2005) · cites this paper as Blitzer, Brin, & Stewart, 1998
In the citing paper
“Several studies have demonstrated that participants generally rate their voices as moderately to severely affected by SD (Aronson et al., 1993; Benninger et al., 2001; Blitzer et al., 1998; Hogikyan et al., 2001; Langeveld, Luteijn et al., 2001; Langeveld, van Rossum et al., 2001; Rubin et al., 2004; Schonweiler, Wohlfarth, Dengler, & Ptok, 1998).”
From The consequences of spasmodic dysphonia on communication-related quality of life: A qualitative study of the insider's experiences (2005) · cites this paper as Blitzer et al., 1998
In the citing paper
“Since its introduction by Blitzer and Brin in 1986, BTX has become the primary treatment for these neurological voice conditions.4,10,11”
From Analysis of Information Needs Among Patients With Neurological Voice Disorders Treated With Laryngeal Botulinum Toxin Injection (2026) · cites this paper as [10]
Citations
Cites
Kokmen, E. (1976) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1976.03270020071039 · Cited by 1,003
Ichinose, H., Ohye, T., Takahashi, E.-I., Seki, N., Hori, T.-A., Segawa, M., Nomura, Y., Endo, K., Tanaka, H., Tsuji, S., et al. (1994) · Nature Genetics · doi:10.1038/ng1194-236 · Cited by 771
THE ANATOMICAL BASIS OF SYMPTOMATIC HEMIDYSTONIA
MARSDEN, C. D., OBESO, J. A., ZARRANZ, J. J., & LANG, A. E. (1985) · Brain · doi:10.1093/brain/108.2.463 · Cited by 589
Proteolysis of SNAP-25 by types E and A botulinal neurotoxins.
Binz, T., Blasi, J., Yamasaki, S., Baumeister, A., Link, E., Südhof, T. C., Jahn, R., & Niemann, H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42071-0 · Cited by 434
Blitzer, A., Brin, M. F., Fahn, S., & Lovelace, R. E. (1988) · The Laryngoscope · doi:10.1288/00005537-198802000-00015 · Cited by 260
Self-citationDopa‐responsive dystonia: Long‐term treatment response and prognosis
Nygaard, T. G., Marsden, C. D., & Fahn, S. (1991) · Neurology · doi:10.1212/wnl.41.2_part_1.174 · Cited by 244
Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia
Ludlow, C. L., Naunton, R. F., Sectary, S. E., Schulz, G. M., & Hallett, M. (1988) · Neurology · doi:10.1212/wnl.38.8.1220 · Cited by 209
Ae, A. (1985) · Cited by 197
Dystonia in Ashkenazi Jews: Clinical characterization of a founder mutation
Bressman, S. B., de Leon, D., Kramer, P. L., Ozelius, L. J., Brin, M. F., Greene, P. E., Fahn, S., Breakefield, X. O., & Risch, N. J. (1994) · Annals of Neurology · doi:10.1002/ana.410360514 · Cited by 181
Self-citationLaryngeal Dystonia: A Series with Botulinum Toxin Therapy
Blitzer, A., & Brin, M. F. (1991) · Annals of Otology, Rhinology & Laryngology · doi:10.1177/000348949110000201 · Cited by 180
Self-citation
Research works printed but not linked: 3
- Fahn S, 1988, X‐linked recessive dystonia and parkinsonism in Filipino males [abstract], Ann Neurol, 24, 179
- 10.1002/ana.410270203 · DOI
- Koufman JA, 1992, New classification of laryngeal dystonias, The Visible Voice, 1, 1
Cited by
Clinical Practice Guideline: Hoarseness (Dysphonia)
Schwartz, S. R., Cohen, S. M., Dailey, S. H., Rosenfeld, R. M., Deutsch, E. S., Gillespie, M. B., Granieri, E., Hapner, E. R., Kimball, C. E., Krouse, H. J., et al. (2009) · Otolaryngology–Head and Neck Surgery · doi:10.1016/j.otohns.2009.06.744 · Cited by 453
Clinical Practice Guideline: Hoarseness (Dysphonia) (Update)
Stachler, R. J., Francis, D. O., Schwartz, S. R., Damask, C. C., Digoy, G. P., Krouse, H. J., McCoy, S. J., Ouellette, D. R., Patel, R. R., Reavis, C. (. W., et al. (2018) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599817751030 · Cited by 368
The focal dystonias: Current views and challenges for future research
Jinnah, H. A., Berardelli, A., Comella, C., DeFazio, G., DeLong, M. R., Factor, S., Galpern, W. R., Hallett, M., Ludlow, C. L., Perlmutter, J. S., et al. (2013) · Movement Disorders · doi:10.1002/mds.25567 · Cited by 209
Botulinum Toxin: Basic Science and Clinical Uses in Otolaryngology
Blitzer, A., & Sulica, L. (2001) · The Laryngoscope · doi:10.1097/00005537-200102000-00006 · Cited by 194
Self-citationSymptomatic Treatment of Multiple Sclerosis
Henze, T., Rieckmann, P., & Toyka, K. V. (2006) · European Neurology · doi:10.1159/000095699 · Cited by 182
Metadata
- Authors
- Blitzer, A., Brin, M. F., & Stewart, C. F.
- Affiliations
- New York University (US)
- Corresponding author
- Blitzer, Andrew
- Venue
- The Laryngoscope
- Publisher
- Wiley
- Published
- 1998-10
- Volume
- 108
- Issue
- 10
- Pages
- 1435-1441
- ISSN
- 0023-852X (ISSN-L)
- 1531-4995
- OpenAlex
- W2002504714
- Cited by
- 391
- References
- 34
- Citations by year
- 2026: 15 · 2025: 15 · 2024: 8 · 2023: 8 · 2022: 18 · 2021: 17 · 2020: 17 · 2019: 9 · 2018: 20 · 2017: 17 · 2016: 19 · 2015: 10 · 2014: 22 · 2013: 8 · 2012: 12
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Laryngoscope (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Health Professions › Speech and Hearing › Voice and Speech Disorders
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory and Cough-Related Research
- Keywords
- spasmodic dysphonia, laryngeal dystonia, botulinum toxin type A, adductor spasmodic dysphonia, abductor spasmodic dysphonia, treatment outcomes, adverse effects, stridor, breathiness
- MeSH terms
- Adult, Electromyography, Female, Humans, Male, Neuromuscular Agents, Retrospective Studies, Voice Disorders, Treatment Outcome, Botulinum Toxins, Type A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12‐year experience in more than 900 patients. https://app.cochat.ai/papers/10.1097/00005537-199810000-00003
- The paper
- Blitzer, A., Brin, M. F., & Stewart, C. F. (1998). Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12‐year experience in more than 900 patients. The Laryngoscope. https://doi.org/10.1097/00005537-199810000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.